ARCA Total Current Liabilities from 2010 to 2024
| ABIO Stock | USD 3.25 0.04 1.25% |
Total Current Liabilities | First Reported 1997-03-31 | Previous Quarter 992 K | Current Value 637 K | Quarterly Volatility 12.1 M |
Check ARCA Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARCA main balance sheet or income statement drivers, such as Depreciation And Amortization of 105.5 K, Interest Expense of 637.9 K or Selling General Administrative of 7.2 M, as well as many exotic indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.63. ARCA financial statements analysis is a perfect complement when working with ARCA Biopharma Valuation or Volatility modules.
ARCA | Total Current Liabilities |
Latest ARCA Biopharma's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of ARCA Biopharma over the last few years. Total Current Liabilities is an item on ARCA Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ARCA Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. ARCA Biopharma's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ARCA Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
ARCA Total Current Liabilities Regression Statistics
| Arithmetic Mean | 1,480,610 | |
| Geometric Mean | 1,207,093 | |
| Coefficient Of Variation | 66.83 | |
| Mean Deviation | 744,712 | |
| Median | 1,200,000 | |
| Standard Deviation | 989,497 | |
| Sample Variance | 979.1B | |
| Range | 3.2M | |
| R-Value | 0.17 | |
| Mean Square Error | 1T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | 38,668 | |
| Total Sum of Squares | 13.7T |
ARCA Total Current Liabilities History
About ARCA Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ARCA Biopharma income statement, its balance sheet, and the statement of cash flows. ARCA Biopharma investors use historical funamental indicators, such as ARCA Biopharma's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although ARCA Biopharma investors may use each financial statement separately, they are all related. The changes in ARCA Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ARCA Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ARCA Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ARCA Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 637 K | 605.1 K |
Pair Trading with ARCA Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ARCA Stock
| 0.85 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.68 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
| 0.48 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of ARCA Biopharma Correlation against competitors. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.